Sumitomo Pharma Co., Ltd.
4506.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥680 | ¥386 | ¥290 | ¥224 |
| - Cash | ¥38 | ¥20 | ¥23 | ¥85 |
| + Debt | ¥263 | ¥309 | ¥305 | ¥374 |
| Enterprise Value | ¥904 | ¥675 | ¥572 | ¥513 |
| Revenue | ¥119 | ¥108 | ¥106 | ¥112 |
| % Growth | 10.3% | 2.2% | -6% | – |
| Gross Profit | ¥74 | ¥64 | ¥66 | ¥71 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| EBITDA | ¥86 | ¥26 | ¥6 | ¥27 |
| % Margin | 72.3% | 24.2% | 5.3% | 24.4% |
| Net Income | ¥88 | ¥11 | ¥2 | ¥53 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS Diluted | 220.63 | 28.21 | 6.08 | 134.53 |
| % Growth | 682.1% | 364% | -95.5% | – |
| Operating Cash Flow | ¥18 | -¥0 | ¥11 | ¥1 |
| Capital Expenditures | -¥1 | -¥1 | -¥2 | -¥2 |
| Free Cash Flow | ¥17 | -¥2 | ¥9 | -¥1 |